|
|
|
|
|
|
|
|
|||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
First published online September 18, 2007
doi: 10.1242/10.1242/jcs.03481
Cell Science at a Glance |
1 Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
2 Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Charlestown, MA, USA
E-mails: mwolfe{at}rics.bwh.harvard.edu; guenette{at}helix.mgh.harvard.edu
 |
Introduction |
|---|
 Top Introduction Knockouts, knockdowns and...APP as a putative...Intracellular interactorsConclusionsReferences |
|---|
(A), which is a proteolytic product derived from the amyloid precursor protein (APP), a type I integral membrane protein (Hardy and Selkoe, 2002
). The discovery of the APP gene was followed by the identification of missense mutations associated with familial, early-onset AD (FAD). These mutations are found in and around the A region of APP, and affect the production or aggregation properties of A. Those APP mutations near the C-terminal region of the A sequence specifically lead to increased proportions of the highly aggregation-prone 42-residue form of A (A42). Although two other APP-like proteins – APLP1 and APLP2 – are known, the A regions are not well conserved, and no FAD mutations have been identified in these genes.
Production of A involves sequential proteolysis by - and 
-secretases, the former being a membrane-tethered protease and the latter a membrane-embedded complex with presenilin as the catalytic component (Haass, 2004). Presenilins are also sites of many FAD-associated missense mutations which alter the -secretase cleavage event to skew production towards A42. Together, these findings strongly supported the hypothesis that this peptide is indeed a pathogenic entity for AD. Besides presenilin, which is an unusual intramembranous aspartyl protease (Xia and Wolfe, 2003), other members of the -secretase complex include the membrane proteins nicastrin, APH1, and PEN2; this protease complex cuts within the transmembrane domain of APP and determines the length of A peptides. The pepsin-like aspartyl protease -secretase sheds the ectodomain of APP, releasing the soluble protein sAPP-. Alternative shedding by metalloproteases called 
-secretases (e.g. ADAM17) leads to proteolysis within the A region and produces a slightly longer soluble protein sAPP-. After ectodomain shedding, -secretase cuts the remaining membrane-bound stub to release the APP intracellular domain (AICD) as well as either A (via the -secretase pathway) or the N-terminally truncated peptide p3 (via the -secretase pathway). A in turn can be degraded by proteases such as the insulin-degrading enzyme (IDE) (Farris et al., 2003) and neprilysin (Iwata et al., 2001).
|
). Initial reports speculated that the protein is a cell-surface receptor (Kang et al., 1987). The discovery of interacting proteins, genetic studies in animals, and gene expression profiling have since led to the identification of putative pathways for the APP family associated with cellular and developmental changes. |
Knockouts, knockdowns and transgenics |
|---|
|
TopIntroductionKnockouts, knockdowns and...APP as a putative...Intracellular interactorsConclusionsReferences |
|---|
), while loss of both copies leads to larval lethality (Hornsten et al., 2007; Zambrano et al., 2002). This lethality can be rescued by pan-neuronal expression of the apl-1 ectodomain, which indicates that APP plays a non-cell-autonomous role in development (Horsten et al., 2007). In Drosophila, deletion of the single APP-like gene (Appl) results in only subtle behavioral defects that can be rescued by wild-type but not mutant APPL or APP (Luo et al., 1992), but a later study suggested that deletion and mutation affects kinesin-mediated axonal transport and neuronal viability (Gunawardena and Goldstein, 2001).
In mice, single knockouts of APP gene family members are viable. However, APP knockout mice display several phenotypes, which include impairment in spatial learning and long-term potentiation (LTP). These deficits can be rescued by a knock-in allele of sAPP-, indicating that the ectodomain of APP is sufficient for APP function in the adult brain (Ring et al., 2007). By contrast, the APP-APLP2 and APLP1-APLP2 double knockout or APP-APLP1-APLP2 triple knockout result in loss of viability. APP-APLP2 double knockout mice have a neuromuscular junction defect (Wang et al., 2005), whereas the triple knockout has neuronal ectopias resembling type II lissencephaly (Herms et al., 2004). These findings demonstrated the importance of the APP family in development, and suggest functional redundancy consistent with a role in neuronal cell adhesion and migration. Interestingly, knocking out Fe65, an intracellular APP-interacting protein, in worms (Zambrano et al., 2002) or the combined FE65-FE65L1 knockout in mice (Guénette et al., 2006) results in phenotypes strikingly similar to those seen when APP genes are knocked out. This suggests that these proteins are functionally as well as physically connected (see below).
APP-transgenic animals provide further clues to potential physiological roles. Overexpression of APP family members in Drosophila affects development of the peripheral nervous system, and genetic analyses indicate Notch gain-of-function phenotypes may be due to interaction of APP with Numb, a negative regulator of Notch signaling (Merdes et al., 2004). Other reports suggest that APP and Notch interact directly through their transmembrane domains (Chen et al., 2006; Fassa et al., 2005; Oh et al., 2005). Transgenic APP flies also show increased axonal arborization, which critically depends on the cytosolic domain and its interaction with Abl kinase (Leyssen et al., 2005).
Brain injury induces APP expression, which suggests that APP plays a repair role in this context. The correlation of AD with head trauma may reflect an increase in APP expression, with A generation being an unfortunate epiphenomenon. APP-transgenic mice have been generated in the hope of reproducing the A-containing plaques of AD and testing therapeutic candidates. A recent report shows that pathological, physiological and behavioral deficits in APP-transgenic mice are not seen in those with a mutation at a caspase-cleavage site in the intracellular domain (Galvan et al., 2006) and yet still produce A and amyloid deposits. This suggests a role for the APP intracellular domain and possibly for the caspase-released cytosolic tail in the pathogenesis of AD.
|
APP as a putative receptor |
|---|
|
TopIntroductionKnockouts, knockdowns and...APP as a putative...Intracellular interactorsConclusionsReferences |
|---|
; Selkoe and Kopan, 2003). Notch is essential for many differentiation events during development and adulthood. Signaling is initiated by interaction with cognate ligands, which triggers shedding of the Notch ectodomain by ADAM10 and ADAM17. These metalloproteases also shed the ectodomain of APP through the -secretase pathway (Buxbaum et al., 1998; Lammich et al., 1999). Interestingly, the ADAM17-mediated shedding of APP can be stimulated by phorbol esters and other means of activating protein kinase C (Buxbaum et al., 1993).
The membrane-associated stub of Notch that remains is then cut by -secretase (De Strooper et al., 1999), releasing an intracellular domain that translocates to the nucleus and interacts with certain transcription factors to control gene expression and cell fate. Thus, the thinking was that APP may likewise have extracellular ligands and that the intracellular domain (AICD) might translocate to the nucleus (Cupers et al., 2001) and interact with factors regulating the expression of certain genes. Alternatively, APP proteolysis may be a mechanism for turning off normal APP functions. In this regard, the proteases are simply degradative, a concept that is especially true for -secretase, which cleaves many type I integral membrane proteins and has even been likened to a proteasome of the membrane (Kopan and Ilagan, 2004).
The search for APP ligands has not been especially fruitful. F-spondin, a secreted neuronal protein purportedly involved in cell-cell interactions, was identified by affinity isolation, and coexpression of this protein prevents shedding of the APP ectodomain by -secretase and reduces A production (Ho and Sudhof, 2004). However, it is unclear whether soluble F-spondin added to cultures has the same effect, or whether the F-spondin–APP interaction occurs when the two proteins are expressed in different cells. Reelin, an extracellular matrix protein essential for cortical development that shares homology with F-spondin, was shown to increase binding of the reelin signaling mediator Dab1 to APP (Hoe et al., 2006b). Furthermore, fewer reelin-expressing pyramidal neurons are observed in the entorhinal cortex of APP-transgenic mice and AD brains (Chin et al., 2007). The Nogo-66 receptor, implicated in axonal sprouting in the adult CNS, has also been reported to interact with the APP ectodomain and inhibit A production (Park et al., 2006). LRP and SORL1 (SorLA, LR11) also bind to the APP ectodomain and influence A production (Andersen et al., 2005; Bu et al., 2006). Indirect triggering of - and -secretase cleavage of APP has been reported for platelet-derived growth factor and certain cytokines (Gianni et al., 2003; Liao et al., 2004), and as mentioned above, activation of protein kinase C leads to APP proteolysis through the -secretase pathway (Buxbaum et al., 1993).
sAPP released from the membrane may serve as a signaling molecule. Evidence suggests that the shed ectodomain plays a role in the growth of fibroblasts in culture (Park et al., 2006). sAPP was found to be neuroprotective for primary neurons in culture, preventing elevations in intracellular Ca2+ levels caused by glucose deprivation and raising the excitotoxic threshold of glutamate (Mattson et al., 1993), as well as mediating axonal and dendritic growth (Perez et al., 1997).
APP may also serve as an adhesion molecule: it binds to extracellular matrix proteins such as heparin and collagen (Beher et al., 1996; Multhaup, 1994). Homo- and heterodimerization between the APP family members in adjacent cells has also been suggested to promote intercellular adhesion (Soba et al., 2005). Such a mechanism would be analogous to that of known cell adhesion molecules such as cadherins and nectins. APP and Fe65 have been reported to influence cell motility, and several regulators of actin dynamics were recently found to be regulated by AICD (Guénette et al., 2006; Muller et al., 2007; Sabo et al., 2001; Sabo et al., 2003).
|
Intracellular interactors |
|---|
|
TopIntroductionKnockouts, knockdowns and...APP as a putative...Intracellular interactorsConclusionsReferences |
|---|
; King et al., 2004; Kuan et al., 2006; Muresan and Muresan, 2005; Zheng et al., 1998; Noviello et al., 2003).
APP-binding proteins are also involved in brain development: the Fe65 proteins transmit an APP-dependent signal important for neuronal positioning in the developing cortex; mDab1 plays a key role in reelin signaling in the developing cortex; and Numb is a scaffold protein important for Notch signaling (Guénette et al., 2006; Hoe et al., 2006b; Roncarati et al., 2002). Other APP-tail-binding proteins are implicated in regulating cell cycle progression; these include Go, PAK3, APP-BP1 (Chen et al., 2007; Chen et al., 2003; Giambarella et al., 1997; McPhie et al., 2003). In the case of Go and PAK3, this has been associated with FAD-linked APP mutations. Interaction of the APP tail with Shc and Grb2 is thought to lead to signaling through the Ras-Raf-MAPK pathway, and APP-Shc-Grb2 complexes have been reported to be increased in AD patients (Russo et al., 2005).
The APP C-terminus is a substrate for several enzymes. Proteolysis by the -secretase complex occurs within the 99-residue C-terminal tail of APP, and binding to presenilins by this APP stub has been demonstrated. Phosphorylation of the intracellular tail is mediated by several kinases. These include the Ser/Thr kinases JNK, CDK5, GSK-3, which phosphorylate Thr668, and the non-receptor tyrosine kinases Abl and Src, and nerve growth factor tyrosine-kinase receptor A (TrkA), which phosphorylate Tyr682 (Russo et al., 2005). Phosphorylation has been shown to regulate which proteins bind to the APP tail. JNK phosphorylation leads to preferential binding to JIP-1, whereas JIP-2 binds to phosphorylated and unphosphorylated APP equally well (Muresan and Muresan, 2005). A Glu substitution at Thr668, mimicking phosphorylation, destabilizes the Fe65-APP interaction (Ando et al., 2001), whereas Tyr682 phosphorylation facilitates binding of Shc and Grb2 to APP (Russo et al., 2005).
A recent study shows binding of the APP tail to hARD1, an acetylase subunit, but modification of the APP tail by this acetylase has not been examined (Asaumi et al., 2005). In addition, prolyl isomerases, Pin1 and FKBP12, bind to the APP C-terminus. Pin1 binds Thr668 phosphorylated APP and accelerates its isomerization (Pastorino et al., 2006). There are numerous reports addressing the impact of APP-binding proteins on APP proteolysis and A generation (Russo et al., 2005). In the case of Fe65 and Dab1, the effects are cell type dependent, possibly owing to the existing complement of competing cellular APP-binding proteins in each cell type (Hoe et al., 2006a; Hoe et al., 2006b; Parisiadou and Efthimiopoulos, 2007). In addition, tripartite complexes involving APP-binding proteins, APP and other molecules, such as alcadein-X11L-APP and LRP-Fe65-APP, have been shown to influence A generation (Araki et al., 2004; Yoon et al., 2005).
The APP-interacting protein that has generated the most interest is Fe65, because a ternary complex consisting of Fe65, APP and the histone acetyltransferase Tip60 has been shown to activate transcription (Baek et al., 2002; Cao and Sudhof, 2001; Cao and Sudhof, 2004). Most of the evidence supporting a role for an APP-Fe65-Tip60 complex in transcriptional activation comes from studies using an artificial reporter system in cells overexpressing APP or AICD. Although AICD is rapidly degraded by IDE (Edbauer et al., 2002), it can be detected in primary neurons during differentiation in culture (Kimberly et al., 2005). Nuclear translocation of Fe65 is required for transactivation, and -secretase-mediated cleavage of APP can facilitate this event. However, one report shows APP-Fe65-Tip60 signaling occurring independently of -secretase cleavage (Hass and Yankner, 2005). Moreover, Fe65-GAL4 expression alone was recently shown to mediate transcriptional activation of the reporter, which could be partly blocked by knocking down APP or overexpressing Tip60 (Yang et al., 2006).
Intracellular and extracellular factors that regulate Fe65-APP-dependent transactivation have also been identified. 14-3-3 can bind both APP and Fe65 and facilitate transcriptional activation (Sumioka et al., 2005). 17- estradiol was reported to repress transcriptional activation through sequestration of Fe65 away from the Cd82 (KAI-1) promoter through increased binding of estrogen receptor and Fe65 (Bao et al., 2007). Candidate AICD-target genes have been suggested (e.g. tetraspanin CD82, APP, GSK3 and neprilysin), although one report provides evidence that the expression of none of these is -secretase dependent and that Fe65 has a weak stimulating effect on various promoters (Hebert et al., 2006). Several novel AICD-regulated candidate genes have been identified as regulators of actin dynamics; however, a direct association of Fe65 or AICD with their promoters remains to be demonstrated (Muller et al., 2007). Thus, although the APP-Fe65 interaction is probably physiological, the identity of downstream effectors remains unclear. In a very recent study, the EGFR promoter was identified as a target for AICD and FE65 in mouse brain and embryonic fibroblasts. Binding of AICD and FE65 to the EGFR promoter represses EGFR transcription (Zhang et al., 2007).
AICD has also been implicated in regulating phosphoinositide-mediated Ca2+ signaling (Leissring et al., 2002). Presenilin and -secretase activity were crucial to this process, which involves release of endoplasmic reticulum Ca2+ stores. Cells lacking APP show deficits in Ca2+ signaling that can be rescued by constructs containing the AICD region, including AICD alone, but not by constructs lacking this domain. The in vivo relevance of this cellular effect of APP is unknown. However, a recent report showed that AICD is the only APP proteolytic product that correlates with enhanced spatial memory in mice overproducing wild-type human APP. The findings of Ring et. al. (2007) show that sAPP- is essential for spatial learning and those of Ma et al. (2007) suggest that AICD may, in the presence of the APP ectodomain, enhance spatial memory (Ring et. al. 2007; Ma et al. 2007).
|
Conclusions |
|---|
|
TopIntroductionKnockouts, knockdowns and...APP as a putative...Intracellular interactorsConclusionsReferences |
|---|
|
References |
|---|
|
TopIntroductionKnockouts, knockdowns and...APP as a putative...Intracellular interactorsConclusionsReferences |
|---|
Andersen, O. M., Reiche, J., Schmidt, V., Gotthardt, M., Spoelgen, R., Behlke, J., von Arnim, C. A., Breiderhoff, T., Jansen, P., Wu, X. et al. (2005). Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc. Natl. Acad. Sci. USA 102, 13461-13466.
Ando, K., Iijima, K. I., Elliott, J. I., Kirino, Y. and Suzuki, T. (2001). Phosphorylation-dependent regulation of the interaction of amyloid precursor protein with Fe65 affects the production of beta-amyloid. J. Biol. Chem. 276, 40353-40361.
Annaert, W. and De Strooper, B. (1999). Presenilins: molecular switches between proteolysis and signal transduction. Trends Neurosci. 22, 439-443.[Medline]
Araki, Y., Miyagi, N., Kato, N., Yoshida, T., Wada, S., Nishimura, M., Komano, H., Yamamoto, T., De Strooper, B., Yamamoto, K. et al. (2004). Coordinated metabolism of Alcadein and amyloid beta-protein precursor regulates FE65-dependent gene transactivation. J. Biol. Chem. 279, 24343-24354.
Asaumi, M., Iijima, K., Sumioka, A., Iijima-Ando, K., Kirino, Y., Nakaya, T. and Suzuki, T. (2005). Interaction of N-terminal acetyltransferase with the cytoplasmic domain of beta-amyloid precursor protein and its effect on A beta secretion. J. Biochem. 137, 147-155.
Baek, S. H., Ohgi, K. A., Rose, D. W., Koo, E. H., Glass, C. K. and Rosenfeld, M. G. (2002). Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. Cell 110, 55-67.[CrossRef][Medline]
Bao, J., Cao, C., Zhang, X., Jiang, F., Nicosia, S. V. and Bai, W. (2007). Suppression of beta-amyloid precursor protein signaling into the nucleus by estrogens mediated through complex formation between the estrogen receptor and Fe65. Mol. Cell. Biol. 27, 1321-1333.
Beher, D., Hesse, L., Masters, C. L. and Multhaup, G. (1996). Regulation of amyloid protein precursor (APP) binding to collagen and mapping of the binding sites on APP and collagen type I. J. Biol. Chem. 271, 1613-1620.
Bu, G., Cam, J. and Zerbinatti, C. (2006). LRP in amyloid-beta production and metabolism. Ann. N. Y. Acad. Sci. 1086, 35-53.
Buxbaum, J. D., Koo, E. H. and Greengard, P. (1993) Protein phosphorylation inhibits production of Alzheimer amyloid beta/A4 peptide. Proc. Natl. Acad. Sci. USA. 90, 9195-9198.
Buxbaum, J. D., Liu, K. N., Luo, Y., Slack, J. L., Stocking, K. L., Peschon, J. J., Johnson, R. S., Castner, B. J., Cerretti, D. P. and Black, R. A. (1998). Evidence that tumor necrosis factor converting enzyme is involved in regulated -secretase cleavage of the Alzheimer's amyloid protein precursor. J. Biol. Chem. 273, 27765-27767.
Cao, X. and Sudhof, T. C. (2001). A transcriptionally active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 293, 115-120.
Cao, X. and Sudhof, T. C. (2004). Dissection of APP-dependent transcriptional transactivation. J. Biol. Chem. 279, 24601-24611.
Chen, C. D., Oh, S. Y., Hinman, J. D. and Abraham, C. R. (2006). Visualization of APP dimerization and APP-Notch2 heterodimerization in living cells using bimolecular fluorescence complementation. J. Neurochem. 97, 30-43.[CrossRef][Medline]
Chen, Y., Liu, W., McPhie, D. L., Hassinger, L. and Neve, R. L. (2003). APP-BP1 mediates APP-induced apoptosis and DNA synthesis and is increased in Alzheimer's disease brain. J. Cell Biol. 163, 27-33.
Chen, Y., Bodles, A. M., McPhie, D. L., Neve, R. L., Mrak, R. E. and Griffin, W. S. (2007). APP-BP1 inhibits Abeta42 levels by interacting with Presenilin-1. Mol. Neurodegener. 2, 3.[CrossRef][Medline]
Chin, J., Massaro, C. M., Palop, J. J., Thwin, M. T., Yu, G. Q., Bien-Ly, N., Bender, A. and Mucke, L. (2007). Reelin depletion in the entorhinal cortex of human amyloid precursor protein transgenic mice and humans with Alzheimer's disease. J. Neurosci. 27, 2727-2733.
Cupers, P., Orlans, I., Craessaerts, K., Annaert, W. and De Strooper, B. (2001). The amyloid precursor protein (APP)-cytoplasmic fragment generated by gamma-secretase is rapidly degraded but distributes partially in a nuclear fraction of neurones in culture. J. Neurochem. 78, 1168-1178.[CrossRef][Medline]
De Strooper, B. and Annaert, W. (2000). Proteolytic processing and cell biological functions of the amyloid precursor protein. J. Cell Sci. 113, 1857-1870.[Abstract]
De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J. S., Schroeter, E. H., Schrijvers, V., Wolfe, M. S., Ray, W. J. et al. (1999). A presenilin-1-dependent -secretase-like protease mediates release of Notch intracellular domain. Nature 398, 518-522.[CrossRef][Medline]
Edbauer, D., Willem, M., Lammich, S., Steiner, H. and Haass, C. (2002). Insulin-degrading enzyme rapidly removes the beta-amyloid precursor protein intracellular domain (AICD). J. Biol. Chem. 277, 13389-13393.
Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J. and Guénette, S. (2003). Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. USA 100, 4162-4167.
Fassa, A., Mehta, P. and Efthimiopoulos, S. (2005). Notch 1 interacts with the amyloid precursor protein in a Numb-independent manner. J. Neurosci. Res. 82, 214-224.[CrossRef][Medline]
Galvan, V., Gorostiza, O. F., Banwait, S., Ataie, M., Logvinova, A. V., Sitaraman, S., Carlson, E., Sagi, S. A., Chevallier, N., Jin, K. et al. (2006). Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc. Natl. Acad. Sci. USA 103, 7130-7135.
Giambarella, U., Yamatsuji, T., Okamoto, T., Matsui, T., Ikezu, T., Murayama, Y., Levine, M. A., Katz, A., Gautam, N. and Nishimoto, I. (1997). G protein betagamma complex-mediated apoptosis by familial Alzheimer's disease mutant of APP. EMBO J. 16, 4897-4907.[CrossRef][Medline]
Gianni, D., Zambrano, N., Bimonte, M., Minopoli, G., Mercken, L., Talamo, F., Scaloni, A. and Russo, T. (2003). Platelet-derived growth factor induces the beta-gamma-secretase-mediated cleavage of Alzheimer's amyloid precursor protein through a Src-Rac-dependent pathway. J. Biol. Chem. 278, 9290-9297.
Guénette, S., Chang, Y., Hiesberger, T., Richardson, J. A., Eckman, C. B., Eckman, E. A., Hammer, R. E. and Herz, J. (2006). Essential roles for the FE65 amyloid precursor protein-interacting proteins in brain development. EMBO J. 25, 420-431.[CrossRef][Medline]
Gunawardena, S. and Goldstein, L. S. (2001). Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron 32, 389-401.[CrossRef][Medline]
Haass, C. (2004). Take five – BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. EMBO J. 23, 483-488.[CrossRef][Medline]
Hardy, J. and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
Hass, M. R. and Yankner, B. A. (2005). A {gamma}-secretase-independent mechanism of signal transduction by the amyloid precursor protein. J. Biol. Chem. 280, 36895-36904.
Hebert, S. S., Serneels, L., Tolia, A., Craessaerts, K., Derks, C., Filippov, M. A., Muller, U. and De Strooper, B. (2006). Regulated intramembrane proteolysis of amyloid precursor protein and regulation of expression of putative target genes. EMBO Rep. 7, 739-745.[CrossRef][Medline]
Herms, J., Anliker, B., Heber, S., Ring, S., Fuhrmann, M., Kretzschmar, H., Sisodia, S. and Muller, U. (2004). Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members. EMBO J. 23, 4106-4115.[CrossRef][Medline]
Ho, A. and Sudhof, T. C. (2004). Binding of F-spondin to amyloid-{beta} precursor protein: a candidate amyloid-{beta} precursor protein ligand that modulates amyloid-{beta} precursor protein cleavage. Proc. Natl. Acad. Sci. USA 101, 2548-2553.
Hoe, H. S., Magill, L. A., Guénette, S., Fu, Z., Vicini, S. and Rebeck, G. W. (2006a). FE65 interaction with the ApoE receptor ApoEr2. J. Biol. Chem. 281, 24521-24530.
Hoe, H. S., Tran, T. S., Matsuoka, Y., Howell, B. W. and Rebeck, G. W. (2006b). DAB1 and Reelin effects on amyloid precursor protein and ApoE receptor 2 trafficking and processing. J. Biol. Chem. 281, 35176-35185.
Hornsten, A., Lieberthal, J., Fadia, S., Malins, R., Ha, L., Xu, X., Daigle, I., Markowitz, M., O'Connor, G., Plasterk, R. et al. (2007). APL-1, a Caenorhabditis elegans protein related to the human beta-amyloid precursor protein, is essential for viability. Proc. Natl. Acad. Sci. USA 104, 1971-1976.
Iwata, N., Tsubuki, S., Takaki, Y., Shirotani, K., Lu, B., Gerard, N. P., Gerard, C., Hama, E., Lee, H. J. and Saido, T. C. (2001). Metabolic regulation of brain abeta by neprilysin. Science 292, 1550-1552.
Kamal, A., Stokin, G. B., Yang, Z., Xia, C. H. and Goldstein, L. S. (2000). Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I. Neuron 28, 449-459.[CrossRef][Medline]
Kang, J., Lemaire, H. G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K. H., Multhaup, G., Beyreuther, K. and Muller-Hill, B. (1987). The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733-736.[CrossRef][Medline]
Kimberly, W. T., Zheng, J. B., Town, T., Flavell, R. A. and Selkoe, D. J. (2005). Physiological regulation of the beta-amyloid precursor protein signaling domain by c-Jun N-terminal kinase JNK3 during neuronal differentiation. J. Neurosci. 25, 5533-5543.
King, G. D., Cherian, K. and Turner, R. S. (2004). X11alpha impairs gamma- but not beta-cleavage of amyloid precursor protein. J. Neurochem. 88, 971-982.[Medline]
Kopan, R. and Ilagan, M. X. (2004). Gamma-secretase: proteasome of the membrane? Nat. Rev. Mol. Cell Biol. 5, 499-504.[CrossRef][Medline]
Kuan, Y. H., Gruebl, T., Soba, P., Eggert, S., Nesic, I., Back, S., Kirsch, J., Beyreuther, K. and Kins, S. (2006). PAT1a modulates intracellular transport and processing of amyloid precursor protein (APP), APLP1, and APLP2. J. Biol. Chem. 281, 40114-40123.
Lammich, S., Kojro, E., Postina, R., Gilbert, S., Pfeiffer, R., Jasionowski, M., Haass, C. and Fahrenholz, F. (1999). Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc. Natl. Acad. Sci. USA 96, 3922-3927.
Leissring, M. A., Murphy, M. P., Mead, T. R., Akbari, Y., Sugarman, M. C., Jannatipour, M., Anliker, B., Muller, U., Saftig, P., De Strooper, B. et al. (2002). A physiologic signaling role for the gamma-secretase-derived intracellular fragment of APP. Proc. Natl. Acad. Sci. USA 99, 4697-4702.
Leyssen, M., Ayaz, D., Hebert, S. S., Reeve, S., De Strooper, B. and Hassan, B. A. (2005). Amyloid precursor protein promotes post-developmental neurite arborization in the Drosophila brain. EMBO J. 24, 2944-2955.[CrossRef][Medline]
Liao, Y. F., Wang, B. J., Cheng, H. T., Kuo, L. H. and Wolfe, M. S. (2004). Tumor necrosis factor-{alpha}, interleukin-1{beta}, and interferon-{gamma} stimulate {gamma}-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J. Biol. Chem. 279, 49523-49532.
Luo, L., Tully, T. and White, K. (1992). Human amyloid precursor protein ameliorates behavioral deficit of flies deleted for Appl gene. Neuron 9, 595-605.[CrossRef][Medline]
Ma, H., Lesne, S., Kotilinek, L., Steidl-Nichols, J. V., Sherman, M., Younkin, L., Younkin, S., Forster, C., Sergeant, N., Delacourte, A. et al. (2007). Involvement of beta-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. Proc. Natl. Acad. Sci. USA 104, 8167-8172.
Mattson, M. P., Cheng, B., Culwell, A. R., Esch, F. S., Lieberburg, I. and Rydel, R. E. (1993). Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 10, 243-254.[CrossRef][Medline]
McPhie, D. L., Coopersmith, R., Hines-Peralta, A., Chen, Y., Ivins, K. J., Manly, S. P., Kozlowski, M. R., Neve, K. A. and Neve, R. L. (2003). DNA synthesis and neuronal apoptosis caused by familial Alzheimer disease mutants of the amyloid precursor protein are mediated by the p21 activated kinase PAK3. J. Neurosci. 23, 6914-6927.
Merdes, G., Soba, P., Loewer, A., Bilic, M. V., Beyreuther, K. and Paro, R. (2004). Interference of human and Drosophila APP and APP-like proteins with PNS development in Drosophila. EMBO J. 23, 4082-4095.[CrossRef][Medline]
Muller, T., Concannon, C. G., Ward, M. W., Walsh, C. M., Tirniceriu, A. L., Tribl, F., Kogel, D., Prehn, J. H. and Egensperger, R. (2007). Modulation of gene expression and cytoskeletal dynamics by the amyloid precursor protein intracellular domain (AICD). Mol. Biol. Cell 18, 201-210.
Multhaup, G. (1994). Identification and regulation of the high affinity binding site of the Alzheimer's disease amyloid protein precursor (APP) to glycosaminoglycans. Biochimie 76, 304-311.[Medline]
Muresan, Z. and Muresan, V. (2005). Coordinated transport of phosphorylated amyloid-beta precursor protein and c-Jun NH2-terminal kinase-interacting protein-1. J. Cell Biol. 171, 615-625.
Noviello, C., Vito, P., Lopez, P., Abdallah, M. and D'Adamio, L. (2003) Autosomal recessive hypercholesterolemia protein interacts with and regulates the cell surface level of Alzheimer's amyloid beta precursor protein. J. Biol. Chem. 278, 31843-31847.
Oh, S. Y., Ellenstein, A., Chen, C. D., Hinman, J. D., Berg, E. A., Costello, C. E., Yamin, R., Neve, R. L. and Abraham, C. R. (2005). Amyloid precursor protein interacts with notch receptors. J. Neurosci. Res. 82, 32-42.[CrossRef][Medline]
Parisiadou, L. and Efthimiopoulos, S. (2007). Expression of mDab1 promotes the stability and processing of amyloid precursor protein and this effect is counteracted by X11alpha. Neurobiol. Aging 28, 377-388.[CrossRef][Medline]
Park, J. H., Gimbel, D. A., GrandPre, T., Lee, J. K., Kim, J. E., Li, W., Lee, D. H. and Strittmatter, S. M. (2006). Alzheimer precursor protein interaction with the Nogo-66 receptor reduces amyloid-beta plaque deposition. J. Neurosci. 26, 1386-1395.
Pastorino, L., Sun, A., Lu, P. J., Zhou, X. Z., Balastik, M., Finn, G., Wulf, G., Lim, J., Li, S. H., Li, X. et al. (2006). The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature 440, 528-534.[CrossRef][Medline]
Perez, R. G., Zheng, H., Van der Ploeg, L. H. and Koo, E. H. (1997). The beta-amyloid precursor protein of Alzheimer's disease enhances neuron viability and modulates neuronal polarity. J. Neurosci. 17, 9407-9414.
Ring, S., Weyer, S. W., Kilian, S. B., Waldron, E., Pietrzik, C. U., Filippov, M. A., Herms, J., Buchholz, C., Eckman, C. B., Korte, M., et al. (2007) The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice. J. Neurosci. 27, 7817-26.
Roncarati, R., Sestan, N., Scheinfeld, M. H., Berechid, B. E., Lopez, P. A., Meucci, O., McGlade, J. C., Rakic, P. and D'Adamio, L. (2002). The gamma-secretase-generated intracellular domain of beta-amyloid precursor protein binds Numb and inhibits Notch signaling. Proc. Natl. Acad. Sci. USA 99, 7102-7107.
Russo, C., Venezia, V., Repetto, E., Nizzari, M., Violani, E., Carlo, P. and Schettini, G. (2005). The amyloid precursor protein and its network of interacting proteins: physiological and pathological implications. Brain Res. Brain Res. Rev. 48, 257-264.[CrossRef][Medline]
Sabo, S. L., Ikin, A. F., Buxbaum, J. D. and Greengard, P. (2001). The Alzheimer amyloid precursor protein (APP) and FE65, an APP-binding protein, regulate cell movement. J. Cell Biol. 153, 1403-1414.
Sabo, S. L., Ikin, A. F., Buxbaum, J. D. and Greengard, P. (2003). The amyloid precursor protein and its regulatory protein, FE65, in growth cones and synapses in vitro and in vivo. J. Neurosci. 23, 5407-5415.
Selkoe, D. and Kopan, R. (2003). Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu. Rev. Neurosci. 26, 565-597.[CrossRef][Medline]
Soba, P., Eggert, S., Wagner, K., Zentgraf, H., Siehl, K., Kreger, S., Lower, A., Langer, A., Merdes, G., Paro, R. et al. (2005). Homo- and heterodimerization of APP family members promotes intercellular adhesion. EMBO J. 24, 3624-3634.[CrossRef][Medline]
Sumioka, A., Nagaishi, S., Yoshida, T., Lin, A., Miura, M. and Suzuki, T. (2005). Role of 14-3-3gamma in FE65-dependent gene transactivation mediated by the amyloid beta-protein precursor cytoplasmic fragment. J. Biol. Chem. 280, 42364-42374.
Wang, P., Yang, G., Mosier, D. R., Chang, P., Zaidi, T., Gong, Y. D., Zhao, N. M., Dominguez, B., Lee, K. F., Gan, W. B. et al. (2005). Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-Like protein 2. J. Neurosci. 25, 1219-1225.
Xia, W. and Wolfe, M. S. (2003). Intramembrane proteolysis by presenilin and presenilin-like proteases. J. Cell Sci. 116, 2839-2844.
Yang, Z., Cool, B. H., Martin, G. M. and Hu, Q. (2006). A dominant role for FE65 (APBB1) in nuclear signaling. J. Biol. Chem. 281, 4207-4214.
Yoon, I. S., Pietrzik, C. U., Kang, D. E. and Koo, E. H. (2005). Sequences from the low density lipoprotein receptor-related protein (LRP) cytoplasmic domain enhance amyloid beta protein production via the beta-secretase pathway without altering amyloid precursor protein/LRP nuclear signaling. J. Biol. Chem. 280, 20140-20147.
Zambrano, N., Bimonte, M., Arbucci, S., Gianni, D., Russo, T. and Bazzicalupo, P. (2002). feh-1 and apl-1, the Caenorhabditis elegans orthologues of mammalian Fe65 and beta-amyloid precursor protein genes, are involved in the same pathway that controls nematode pharyngeal pumping. J. Cell Sci. 115, 1411-1422.
Zhang, Y. W., Wang, R., Liu, Q., Zhang, H., Liao, F. F. and Xu, H. (2007) Presenilin/gamma-secretase-dependent processing of beta-amyloid precursor protein regulates EGF receptor expression. Proc. Natl. Acad. Sci. USA. 104, 10613-10618.
Zheng, P., Eastman, J., Vande Pol, S. and Pimplikar, S. W. (1998). PAT1, a microtubule-interacting protein, recognizes the basolateral sorting signal of amyloid precursor protein. Proc. Natl. Acad. Sci. USA 95, 14745-14750.
This article has been cited by other articles:
|
|
 |
|
  D. Spasic and W. Annaert Building {gamma}-secretase - the bits and pieces J. Cell Sci., February 15, 2008; 121(4): 413 - 420. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
